Top

Published in:

01-05-2006 | Original Article

2MD, a new anabolic agent for osteoporosis treatment

Authors: Lori A. Plum, Lorraine A. Fitzpatrick, Xiaohong Ma, Neil C. Binkley, Julia B. Zella, Margaret Clagett-Dame, Hector F. DeLuca

Published in: Osteoporosis International | Issue 5/2006

Abstract

Introduction

2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D₃ (2MD) is a new analog of 1α,25-dihydroxyvitamin D₃ (1,25-(OH)₂D₃) that has unique properties (distinct from 1α,25-dihydroxyvitamin D₃) in stimulating osteoblasts to form bone in culture. This analog has now been extensively tested in aged ovariectomized female rats maintained on a diet adequate in calcium and phosphorus.

Methods

Retired female rats obtained from Sprague–Dawley were ovariectomized, and were either dosed with vehicle or 2MD at 5–7 ng/kg body weight each day.

Results

A marked increase in total bone mass resulted during the 28-week study. This increase in bone mass resulted from an increase in both cortical and trabecular bone, with increases to the order of 25% in the cancellous bone. Histomorphometry revealed that 2MD increased bone mass primarily by increasing bone formation. It also revealed little or no effect on bone resorption. The resulting bone is of high quality revealed by histology and biomechanical testing.

Conclusion

Throughout the study, serum calcium remained within the normal range and thus 2MD shows great promise for the treatment of bone diseases characterized by bone loss, including osteoporosis.

US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Rockville, MD

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitla BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed

Deal C, Gideon J (2003) Recombinant human PTH 1–34 (Forteo): an anabolic drug for osteoporosis. Cleveland Clin J Med 70:585–601CrossRef

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Dannata J, Falogh A, Lemmel E-M, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster J-Y (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefPubMed

Sicinski RR, Prahl JM, Smith CM, DeLuca HF (1998) New 1α,25-dihydroxy-19-norvitamin D₃ compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem 41:4662–4674CrossRefPubMed

Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF (2002) A potent analog of 1α,25-dihydroxyvitamin D₃ selectively induces bone formation. Proc Natl Acad Sci USA 99:13487–13491PubMedCrossRef

Yasuda H, Shima N, Nakagawa N, Yamagushi K, Kinosaki M, Mochizuka S-I, Tomoyasu A, Yano K, Gotto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602PubMedCrossRef

Suda T, DeLuca HF, Tanaka Y (1970) Biological activity of 25-hydroxyergocalciferol in rats. J Nutr 100:1049–1052PubMed

Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, Binkley N (2000) Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res 15:872–878PubMedCrossRef

10.

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier P, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595–610PubMedCrossRef

11.

Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT (1998) Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Miner Res 13:1023–1031PubMedCrossRef

12.

Simone WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed

13.

Sibonga JD, Zhang M, Ritman EL, Turner RT (2000) Restoration of bone mass in the severely osteopenic senescent rat. J Gerontol Biol Sci 55A:B71–B78

14.

Markose ER, Stein JL, Stein GS, Lian JB (1990) Vitamin D-mediated modifications in protein-DNA interactions at two promoter elements of the osteocalcin gene. Proc Natl Acad Sci USA 87:1701–1705PubMedCrossRef

15.

Okazaki T, Zajac JD, Igarashi T, Ogata E, Kronenberg HM (1991) Negative regulatory elements in the human parathyroid hormone gene. J Biol Chem 266:21903–21910PubMed

16.

Fraser DR, Kodicek E (1970) Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228:764–766PubMedCrossRef

17.

Holick MF, Schnoes HK, DeLuca HF, Suda T, Cousins RJ (1971) Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 10:2799–2804CrossRefPubMed

18.

Kleerekoper M, Frame B, Villanueva AR, Oliver I, Rao DS, Matkovic V, Parfitt AM, Chir B (1981) Treatment of osteoporosis with sodium fluoride alternating with calcium and vitamin D. In: DeLuca HF, Frost HM, Jee WSS, Johnson CC, Parfitt AM (eds) Osteoporosis: recent advances in pathogenesis and treatment. University Park Press, Baltimore,pp 441–448

19.

Gallagher JC, Riggs BL (1990) Action of 1,25-dihydroxyvitamin D₃ on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 39:30–34CrossRefPubMed

20.

Aloia JF, Vaswani A, Yeh JK, Ellis K. Yasumura S, Cohn SH (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401–408CrossRefPubMed

21.

Dambacher MA, Kranich M, Schacht E, Neff M (1997) Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites? Calcif Tissue Int 60:115–118CrossRefPubMed

22.

Ott SM, Chesnut CH III (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Int Med 110:267–274PubMed

23.

Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G (1990) Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism 39:43–49CrossRefPubMed

24.

Tilyard MW, Spears GFS, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362PubMedCrossRef

25.

Orimo H, Shiraki M, Hayashi T, Nakamura T (1987) Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1α(OH)-vitamin D₃. Bone Miner 3:47–52PubMed

26.

Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T (1994) Effects of 1α-hydroxyvitamin D₃ on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376CrossRefPubMed

27.

Hayashi Y, Fujita T, Inoue T (1992) Decrease of vertebral fracture in osteoporotics by administration of 1α-hydroxy-vitamin D₃. J Bone Miner Metab 10:184–188CrossRef

28.

Riggs BL, Nelson KI (1985) Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis. J Clin Endocrinol Metab 61:457–461PubMedCrossRef

29.

Francis RM, Boyle IT, Moniz C, Sutcliffe AM, Davis BS, Beastall GH, Cowan RA, Downes N (1996) A comparison of the effects of alfacalcidol treatment and vitamin D₂ supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 6:284–290CrossRefPubMed

30.

Need AG, Morris HA, Horowitz M, Nordin BEC (1997) The response to calcitriol therapy in postmenopausal osteoporotic women is a function of initial calcium absorptive status. Calcif Tissue Int 61:6–9CrossRefPubMed

31.

Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Int Med 113:649–655PubMed

32.

Vanhooke JL, Benning MM, Bauer CB, Pike JW, DeLuca HF (2004) Molecular structures of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D₃ hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 43:4101–4110CrossRefPubMed

33.

Yamamoto H, Shevde NK, Warrier A, Plum LA, DeLuca HF, Pike JW (2003) 2-Methylene-19-nor-(20S)-1,25-dihdyroxyvitamin D₃ potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 278:31756–31765CrossRefPubMed

Title: 2MD, a new anabolic agent for osteoporosis treatment
Authors: Lori A. Plum
Lorraine A. Fitzpatrick
Xiaohong Ma
Neil C. Binkley
Julia B. Zella
Margaret Clagett-Dame
Hector F. DeLuca
Publication date: 01-05-2006
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 5/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-005-0036-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

2MD, a new anabolic agent for osteoporosis treatment

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2006

Calcium acquisition rates do not support age-appropriate gains in total body bone mineral content in prepuberty and late puberty in girls with cystic fibrosis

Utility of screening tools for the prediction of low bone mass in African American men

Community-dwelling seniors who present to the emergency department with a fall do not receive Guideline care and their fall risk profile worsens significantly: a 6-month prospective study

Assessment of osteoporosis-website quality

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis

Costs and quality of life associated with osteoporosis-related fractures in Sweden